Acute lymphoblastic leukemia infant · 2 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cyclophosphamide, Etoposide, Methotrexate Variant #01 | KMT2A | R 2 246 | 42d | — | — | — | — | — |
Blinatumomab monotherapy N/A - secondary systemic drug | KMT2A | R 18 | 28d | — | ~7.7 mo | — | — | 2 |
2 of 2 regimens shown